Physician profile

Danielle Milano

Internal Medicine · New York, NY

NPI 1952520603

$20,682.88

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$53.53

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $16,544.33 2019-2022
Viiv Healthcare Company $3,214.73 2020-2022
Janssen Products, Lp $344.60 2020-2022
Novo Nordisk INC $278.88 2019-2020
Echosens North America, INC. $200.50 2019
Theratechnologies INC. $53.53 2023 Egrifta, Trogarzo
Glaxosmithkline, LLC. $29.54 2020
Abbvie INC. $16.77 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Danielle Milano

$20,682.88

in general payments reported 2019-2025

Years
2019-2023
Top company
Gilead Sciences, INC.

https://glasscript.com/doctor/43587/danielle-milano

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.